trending Market Intelligence /marketintelligence/en/news-insights/trending/MgiGL745KrT3fsFKPLtkeg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Sanford C. Bernstein upgrades Cigna over conviction on earnings growth

Part Two IFRS 9 Blog Series: The Need to Upgrade Analytical Tools

2018 US Property Casualty Insurance Market Report


Fintech Funding Flows To Insurtech In February

Lemonade Growing Premiums Faster Than Esurance's Homeowners Business Did

Sanford C. Bernstein upgrades Cigna over conviction on earnings growth

Sanford C. Bernstein analyst Lance Wilkes upgraded his rating on Cigna Corp. stock to "outperform" from "market-perform," based on his conviction on the company's EPS for 2021.

Wilkes said his faith in a 2021 EPS projection of $20.23 is based on the expectation of deal synergies, which Sanford C. Bernstein expects to exceed guidance. The upgraded rating and price target reflect a low valuation that Wilkes said incorporates downside projections on pharmacy benefit manager business, but not the likely EPS growth in 2021.

Wilkes said Cigna would be somewhat insulated should regulations require PBMs to charge only administration fees, rather than retaining spread, as the Express Scripts business has large mail-order and specialty home delivery businesses.

Despite the upgrade, Wilkes is still concerned about the company's growth rate after 2021. He expects Cigna to make another "major capital allocation decision" within the next two to three years, presenting future dilution risks.

Wilkes raised his price target to $205 from $180, compared to an Aug. 5 closing price of $159, or 7.8x projected 2021 EPS. He also raised his EPS estimates to $16.71 from $16.64 for 2019 and to $18.81 from $18.62 for 2020.